BC Innovations | Dec 19, 2018
Distillery Therapeutics

Hematology

INDICATION: Bleeding In vitro and human plasma studies identified a peptide-based plasmin inhibitor that could help treat bleeding. Chemical synthesis and in vitro testing of analogs of a sunflower cyclic peptide serine protease inhibitor in...
BC Week In Review | Sep 19, 2016
Clinical News

LB1148: Phase II started

Leading BioSciences began the double-blind, placebo-controlled, international Phase II PROFILE trial to evaluate 700 mL oral LB1148 given 8-10 hours before undergoing elective bowel resection in about 120 patients. Leading BioSciences Inc. , San Diego, Calif....
BC Innovations | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Thrombin (Factor IIa; F2)

Hematology Self-propelled microparticles loaded with thrombin could help stop bleeding. The porous particles consisted of calcium carbonate and tranexamic acid and, in aqueous solutions, released carbon dioxide that moved the particles through a combination of...
BC Innovations | Nov 12, 2015
Translation in Brief

Going up

In a study published in Science Advances , a Canadian group has demonstrated that rapid gas release allows microparticles to propel themselves and their therapeutic cargo upstream into wounds. The team showed delivery by the particles...
BioCentury | Sep 28, 2015
Emerging Company Profile

Microparticle man

RxMP Therapeutics LLC is developing microparticles harvested from red blood cells to mitigate excessive bleeding during surgery or trauma by promoting clotting at sites of bleeding without instigating unwanted coagulation. Available hemostatics used for acute...
BC Week In Review | Jul 27, 2015
Clinical News

NPH29: Clinical trial data

A double-blind clinical trial in 21 patients showed that 1% NPH29 cream significantly improved both visual scoring and instrumentally measured L*a*b*L values from baseline to day 30 vs. both vehicle cream and tranexamic acid (p<0.005...
BC Week In Review | Sep 16, 2013
Company News

Buderer Drug, Imprimis deal

Imprimis acquired IP for wound healing product IPI-120, a transdermal formulation of tranexamic acid and an antibiotic, from compounding pharmacy Buderer. Imprimis believes the formulation can reduce or stop bleeding and prevent or treat infection....
BC Week In Review | Oct 22, 2012
Clinical News

Cyklokapron tranexamic acid regulatory update

The U.K.'s NICE issued an evidence summary stating that a large international study showed that off-label use of Pfizer's Cyklokapron tranexamic acid to treat and prevent severe bleeding following trauma significantly increases the proportion of...
BC Week In Review | Oct 8, 2012
Clinical News

MDCO-2010: Development discontinued

Medicines Co. discontinued MDCO-2010 after seeing "serious" safety issues in a Phase IIb trial of the compound to reduce blood loss during surgery. Medicines Co. declined to disclose details of the issues, but said it...
BC Extra | Oct 6, 2012
Clinical News

Medicines Co. discontinues MDCO-2010

The Medicines Co. (NASDAQ:MDCO) discontinued MDCO-2010 after seeing "serious" safety issues in a Phase IIb trial of the small molecule serine protease inhibitor to reduce blood loss during surgery. Medicines Co. declined to disclose details...
Items per page:
1 - 10 of 47